Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap740.28M
Enterprise Value712.48M
Trailing P/E113.02
GYRE
(NASDAQ)Gyre Therapeutics, Inc.
$7.12-- (--)
Loading... - Market loading
Gyre Therapeutics (GYRE) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)7.01
Forward Price/Sales6.86
Price/Book (mrq)7.38
Price/Tangible Book (mrq)7.74
Price/FCF (ttm)557.24
Price/OCF (ttm)193.89
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue6.64
EV/Earnings107.12
EV/EBITDA49.72
EV/EBIT59.21
EV/FCF528.15
Stock Price
Current price, 52-week range, and moving averages
Current Price$7.12
1-Day Change3.73%
52-Week High$11.78
52-Week Low$6.11
52-Week Change12.79%
YTD Change6.17%
1-Year Change1.97%
50-Day MA$7.81
200-Day MA$7.69
Avg Volume (30 day)63.54K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding103.97M
Book Value per Share$0.98
Net Cash per Share$0.38
FCF per Share$0.01
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin95.48%
EBITDA Margin (ttm)13.36%
EBIT Margin (ttm)11.22%
Operating Margin (ttm)11.22%
Pretax Margin (ttm)14.24%
Profit Margin (ttm)6.20%
FCF Margin (ttm)1.26%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)6.53%
Return on Assets (ttm)4.17%
Return on Invested Capital (ttm)8.36%
Return on Capital Employed (ttm)8.39%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue107.27M
Gross Profit102.42M
Operating Income12.03M
Pretax Income15.27M
Net Income6.65M
EBITDA14.33M
EBIT12.03M
Diluted EPS$0.06
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow3.88M
Capital Expenditures2.53M
Free Cash Flow1.35M
Growth Rates (YoY)
Year-over-year growth metrics
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)159.38M
Cash & Securities (mrq)40.40M
Net Cash (mrq)39.78M
Net Cash per Share$0.38
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)1.17M
Working Capital (mrq)82.66M
Total Equity (mrq)101.92M
Book Value per Share$0.98
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)6.19
Quick Ratio (mrq)5.64
Debt/Equity (mrq)0.01
Debt/EBITDA (ttm)0.08
Debt/FCF (ttm)0.86
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Ex-Dividend DateJan 13, 2023
Pay DateJan 13, 2023
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield0.88%
FCF Yield0.18%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score21.49
Piotroski F-Score4/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$1.19
Graham Upside/Downside-83.57%
Frequently Asked Questions About Gyre Therapeutics Statistics
What are the key financial metrics for GYRE?
Gyre Therapeutics, Inc. (GYRE) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is GYRE's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Gyre Therapeutics is overvalued or undervalued.
How do I read GYRE's profitability ratios?
Gyre Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do GYRE's debt ratios indicate?
The financial health section shows Gyre Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is GYRE's dividend analysis?
The dividend section covers Gyre Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.